Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most claims about Cialis being tadalafil, on-label ED use, and once-daily/longer window messaging are generally consistent with the provided label. However, claims about pulmonary arterial hypertension and specific “marketing requirements” (e.g., clinicians must confirm suitability; advertising instructs screening for contraindications and drug interactions) are not supported by the provided label text, and “not an OTC product” is not addressed in the supplied sections.
Category Scores
Accurate Statements
Cialis is the brand name for tadalafil.
The label is for CIALIS (tadalafil) tablets.
Cialis is promoted for erectile dysfunction (ED).
Indications (1.1 Erectile Dysfunction).
Cialis marketing emphasizes a once-daily dosing option.
Dosage and Administration (2.2, 2.4) includes once daily use for ED and ED/BPH.
Cialis marketing includes an effect that can last longer than shorter-acting ED treatments.
Use as needed for ED improves erectile function up to 36 hours following dosing (2.1).
Cialis is a prescription medicine and not an over-the-counter product.
Not directly supported in the provided label excerpts.
Cialis promotional materials commonly highlight on-label uses for erectile dysfunction.
Indication (1.1 Erectile Dysfunction) supports ED promotion (label does not discuss marketing materials explicitly, but the on-label use is supported).
Cialis is marketed with a dosing schedule that includes a once-daily option when prescribed.
Once daily dosing options are in Dosage and Administration (2.2 and 2.4).
Cialis promotional materials commonly emphasize a longer window concept compared with some ED medicines taken as needed.
Up to 36 hours following as-needed dosing (2.1).
Cialis promotional materials for ED commonly highlight on-label uses for erectile dysfunction.
Indication (1.1).
Cialis advertising typically reinforces that Cialis is not for everyone.
Warnings include “should not be used in men for whom sexual activity is inadvisable…” (5.1), indicating not for everyone in certain circumstances.
Cialis promotional materials describe side effects and when to seek urgent help in the medical information panel or linked prescribing materials.
Label includes serious adverse-event counseling (e.g., sudden loss of vision/hearing; 5.4, 5.5) and postmarketing adverse reactions (6.2), though the label excerpt does not explicitly mention the format “medical information panel.”
Unsupported Statements
In some markets, Cialis is promoted for benign prostatic hyperplasia (BPH).
Not marked as supported/label mismatch: the label does support BPH indication (1.2), but the statement asserts it is promoted “in some markets,” which is not addressed by the provided label excerpts. Label only confirms indication, not market-specific promotion.
In some markets, Cialis is promoted for pulmonary arterial hypertension.
The provided label excerpts list indications for ED, BPH, and ED/BPH only. No pulmonary arterial hypertension indication is present in the supplied label sections.
Cialis is marketed around “as needed” messaging for specific dosing regimens.
The label includes “use as needed” dosing, but the provided excerpts do not address marketing messaging phrasing.
Cialis is marketed around “once daily” messaging for men who want more consistent dosing without timing intercourse to a dose.
Once daily dosing without regard to timing of sexual activity is in the label (2.2, 2.4), but the claim about marketing positioning is not supported by the provided label excerpt language.
Cialis advertising states that clinicians must screen for contraindications and drug interactions.
The label provides contraindications (4) and interaction-related warnings, but it does not contain the specific instruction that advertising “states clinicians must screen…” as a marketing requirement.
Cialis advertising instructs patients to follow dosing guidance and avoid unsafe combinations.
The label includes patient counseling and contraindications/interaction guidance, but the provided excerpts do not explicitly support the exact advertising instruction framing (“instructs patients…”).
Cialis marketing requires clinicians to confirm suitability.
The label includes guidance to consider cardiovascular status (5.1) and other precautions/contraindications, but it does not explicitly state that “marketing requires clinicians to confirm suitability.”
Contradictions
Low
AI Statement
In some markets, Cialis is promoted for pulmonary arterial hypertension.
Label Reference
Indications and Usage (1.1-1.4) provided only include ED, BPH, and ED/BPH; no pulmonary arterial hypertension indication is included in supplied label sections.
Important Omissions
Any mention of key contraindications (nitrates; GC stimulators such as riociguat) and core interaction precautions (e.g., nitrates contraindication) in the evaluated claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
A claim that Cialis is promoted for pulmonary arterial hypertension is not supported by the provided label excerpts and could mislead intended use if acted upon. Other claims are mostly consistent with label-supported concepts (ED indication; once-daily and effect window).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Pulmonary arterial hypertension promotion is not supported by the provided FDA label excerpts (Indications and Usage).
Suggested Improvement
Limit claims to label-supported indications (ED, BPH, ED/BPH) and to label-supported dosing concepts (as-needed up to 36 hours; once daily dosing with no regard to sexual timing). Avoid presenting marketing process requirements (e.g., “must screen” / “requires clinicians to confirm suitability”) unless directly supported by label text.